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TYPE 2 DIABETES has reached epidemic proportions not only in the US, but worldwide (15a). The major factors contributing to the hyperglycemia of diabetes are multifactorial but are secondary to the failure of the ␤-cells of the pancreas to adequately compensate for the insulin resistance, characterized by decreased whole body insulin-mediated glucose utilization and elevated hepatic glucose output. With regard to enhanced glucose production by the liver, phosphoenolpyruvate carboxykinase (PEPCK) is the key enzyme catalyzing the first step in hepatic gluconeogenesis (5) . Glucagon and stress hormones, such as glucocorticoids, upregulate PEPCK gene expression in hepatocytes via a cyclic AMP (cAMP)-dependent pathway (5) . Alternatively, insulin strongly represses PEPCK transcription through the activation of the phosphoinositide-3 kinase (PI3K) pathway (4) .
Normally, the increase in blood glucose levels after food intake stimulates the secretion of insulin from the pancreas. This increase in blood insulin concentration then leads to the downregulation of PEPCK gene expression and, subsequently, the cessation of gluconeogenesis by the liver (4) . Insulinresistant hepatocytes, however, are unable to effectively convey the insulin signal, leading to a decrease in PEPCK mRNA transcription. Thus, the de novo glucose synthesis persists despite a high blood glucose concentration (12) . The compounds that are able to repress PEPCK expression and overcome insulin resistance could constitute a new class of glucoselowering agents.
Plants have traditionally been a rich source of medicinal compounds for many indications, including diabetes. In fact, metformin is one of the most prescribed glucose-lowering medicines currently used and is derived from a chemical isolated from a plant (19) . Recently, a number of polyphenolic substances from different plant sources were shown to decrease PEPCK expression in vitro (11) , but in vivo data on the effects of these compounds have not been reported.
There are a number of reports (15) about use of plants from the genus Artemisia as a traditional treatment for diabetes. Artemisia dracunculus L. (A. dracunculus), or Russian tarragon, is a perennial herb with a long history of medicinal and culinary use. Recently, the ethanolic extract of A. dracunculus was shown (13) to significantly decrease blood glucose levels in both genetic and chemically induced murine models of diabetes. In addition, the extract significantly decreased PEPCK mRNA expression in the streptozotocin (STZ)-induced diabetic rats, suggesting a potential mode of action (13) . The extract also inhibited aldose reductase, an enzyme involved in many diabetic complications (9) . A phenoxychromone and dihydrochalcone were identified as the specific polyphenolics responsible for most of the activity (9) .
To identify the active compounds from the Artemisia extract that are responsible for its effect on PEPCK regulation, an in vitro assay that requires only milligram quantities of test material was developed. The assay was established in an H4IIE hepatoma cell line, and real-time PCR was used to track changes in PEPCK gene expression in response to the treatment. Studies using inhibitors of specific subcellular biochemical pathways were performed to potentially elucidate a mode of action of the isolated compounds.
METHODS
Chemicals and biochemicals. 8-(4-Chlorophenylthio)-cAMP (8-CPT-cAMP), 5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside, PI3K inhibitor LY-294002, rapamycin, sodium lactate, sodium pyruvate, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were purchased from Sigma Chemicals (St. Louis, MO).
Human insulin (Humulin R) was purchased from Eli Lilly (Indianapolis, IN). All other chemicals, including cell culture media, were obtained from Invitrogen (Carlsbad, CA). PD-184352 was purchased from Toronto Research Chemicals (Toronto, ON, Canada) and compound C from EMD Biosciences (San Diego, CA). Reagents used in RT-PCR, including enzymes, were supplied by Stratagene (La Jolla, CA). Phospho-Akt (Ser 473 ) and Akt2 rabbit MAb were purchased from Cell Signaling Technology (Danvers, MA). The H4IIE cell line (ATCC CRL-1548) was provided by American Type Culture Collection (Manassas, VA).
Plant material. The seeds of A. dracunculus were purchased from Sheffield's Seed (Locke, NY). The plants were grown in hydroponics, and the shoots were harvested and stored at Ϫ20°C.
Extraction. Two kilograms of the shoot material was heated to 80°C with 10 liters of 80% ethanol for 2 h. The extraction was continued for an additional 10 h at 20°C. The extract was filtered through a cheese cloth and evaporated to 1 liter using a rotary evaporator. The extract was then diluted with 1 liter of water and partitioned three times with 2 liters of ethyl acetate. The ethyl acetate fraction was then dried to a slurry using a rotary evaporator, followed by freeze-drying for 48 h.
Purification and isolation of bioactive compounds. Purification, isolation, and identification of bioactive compounds were done as in Longendra et al. (9) . One gram of the dried extract was dissolved in 5 ml of 60% ethanol and 0.5 ml of acetonitrile and purified using a preparatory HPLC. For the initial purification, a Waters 19 ϫ 300 mm symmetry prep C8 reverse-phase column with a particle size of 7 m was used. The mobile phases consisted of two components: solvent A [0.5% American Chemical Society (ACS) grade acetic acid in doubledistilled deionized water, pH 3-3.5] and solvent B (100% acetonitrile). For the initial separation, a gradient run of 5-95% solvent B over 35 min was used at a flow rate of 8 ml/m. Ten fractions at 5-min intervals were collected and tested for PEPCK gene expression. The fractions and subfractions that showed higher inhibition of gene expression were further purified using different conditions. Fractions 7 and 7-8 were purified by altering the gradient conditions described above, with flow rates ranging from 1 to 8 ml/min. Fraction 7-1 was purified using an isocratic condition, with a mobile phase consisting of three components: solvent A (0.5% ACS grade acetic acid in doubledistilled deionized water, pH 3-3.5), solvent B (100% acetonitrile), and solvent C (100% methanol) at a ratio of 5:3:2. Purification of the bioactive subfractions 7-1 and 7-8 gave 6-demethoxycapillarisin and 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone, respectively. The ultraviolet profiles were monitored at wavelengths of 210 and 290 nm.
Identification of compounds. The bioactive compounds were identified using liquid chromatography-mass spectrometry (LC-MS) and 1 H-, 13 C-, and 2D-NMR spectroscopic data. LC-MS system used for analysis includes the Waters (Milford, MA) LC-MS integrity system consisting of a solvent delivery system with a W616 pump and W600S controller, W717 plus autosampler, W996 photodiode array (PDA) detector, and Waters TMD Thermabeam electron impact (EI) single quadrupole mass detector with fixed ionization energy of 70 eV. Data were collected and analyzed with the Waters Millennium version 3.2 software and linked with the sixth edition of the Wiley Registry of mass spectral data, containing 229,119 EI spectra of 200,500 compounds. After the W996 PDA detector the eluent flow was split into two equal flow paths with an adjustable flow splitter (model no. 600-PO10-06; Analytical Scientific Instruments, El Sobrante, CA). One of them was to the Thermabeam EI mass detector and the other to a Varian 1200L (Varian, Palo Alto, CA) triple quadrupole mass detector with electrospray ionization interface operated in either positive or negative ionization mode. The electrospray voltage was Ϫ4.5 kV, heated capillary temperature was 240°C, and sheath gas was air for the negative mode, and electrospray voltage was 5 kV and sheath gas was nitrogen for the positive ionization mode; the mass detector was used in scanning mode from 110 to 1,400 atomic mass units. Data from the Varian 1200L mass detector were collected and compiled using Varian's MS Workstation, version 6.41, SP2. The 1 H-and 13 C-NMR spectra and 2D-NMR experiments were recorded using a Bruker Avance AV-300 NMR spectrometer at 300 ( 1 H) and 75 MHz ( 13 C). The 2D experiments 1 H-1 H COSY (Correlation Spectroscopy), heteronuclear multiple-bond correlation, and edited heteronuclear single quantum coherence were acquired using standard Bruker software. All compounds were measured in CD 3OD.
Cell culture and treatment. The H4IIE hepatoma cells (CRL-1600; American Type Culture Collection) were plated in 24-well tissue culture plates (Greiner Bio One) and were grown to near confluence in Dulbecco's modified Eagle's medium containing 2.5% (vol/vol) newborn calf serum and 2.5% (vol/vol) fetal calf serum. Cells were treated for 8 h with 500 nM dexamethasone and 0.1 mM 8-CTPcAMP (Dex-cAMP) to induce PEPCK gene expression together with different concentrations of test compounds, plant extract, or 10 nM insulin. The fractions were tested at 50 g/ml medium, and the The phosphoenolpyruvate carboxykinase (PEPCK) mRNA was upregulated in all samples except for negative control by incubation H4IIE rat hepatoma cells with 500 nM dexamethasone and 0.1 mM cAMP (Dex-cAMP). PEPCK mRNA was normalized to ␤-actin mRNA. The effect of different fractions and subfractions of Artemisia dracunculus extract or 10 nM insulin on PEPCK gene expression is represented as a ratio of PEPCK mRNA level relative to the response to Dex-cAMP activation alone (fold ratio is equal to 1.0). Lower fold ratio values represent greater inhibitory effect. The data represent the average of 4 experiments Ϯ SE. A: the effect of 10 different fractions (Fr1-10) of Artemisia dracunculus extract on PEPCK mRNA levels in rat hepatoma cells at 50 g/ml. Each of the 10 fractions was collected as sequential 10-min ellutions from the preparatory HPLC column. B: the effect of subfractions of fraction 7 (Fr7-1 to 7-9) on PEPCK mRNA levels in rat hepatoma cells at 25 g/ml.
compounds were tested at doses of 2.5, 5, 10, and 25 g/ml. Three wells were allocated for each treatment as well as for a negative control (untreated cells). For inhibitory assays, cells were pretreated with 20 M LY-294002 for 30 min, washed with phosphate-buffered saline, and incubated for an additional 7 h with Dex-cAMP together with different concentrations of test compounds, plant extract, or 10 nM insulin.
Cell viability assay and dose range determination. Cell viability was measured by the MTT assay (10). The MTT (Sigma) tetrazolium dye assay was performed to measure cell survival in culture after incubation with treatments. MTT (100 g/ml) was added to the medium in each well, and plates were incubated in the cell growth chamber for 5 h. Medium was then removed, and dimethyl sulfoxide (150 l) was added to each well to solubilize the purple formazan crystals created by mitochondrial dehydrogenase reduction of MTT. After 5 min of additional incubation, absorbance was read at 550 nm on a microplate reader spectrophotometer (Molecular Devices, Sunnyvale, CA). The concentrations of test reagents that showed significant cell viability compared with that of the control (dimethyl sulfoxide, 0.1%) were further selected for in vitro gene expression assays. All treatments were performed in duplicate.
Total RNA extraction, purification, and cDNA synthesis. Total RNA was extracted from H4IIE rat hepatoma cells using Trizol reagent (Invitrogen), following the manufacturer's instructions. RNA was quantified spectrophotometrically by absorbance measurements at 260 and 280 nm using the NanoDrop system (NanoDrop Technologies). Quality of RNA was assessed by separation in gel electrophoresis. RNA was then treated with DnaseI (Invitrogen), following the manufacturer's guidelines, to remove any traces of DNA contamination. The cDNAs were synthesized with 2.5 g of RNA for each sample, using Stratascript reverse transcriptase (Stratagene), following the manufacturer's protocol.
Quantitative PCR and data analysis. The synthesized cDNAs were diluted fourfold. Five microliters of each of these diluted samples was used for PCR reactions of 25 l final volume. The other components of the PCR reactions were 0.5 l of 6 M gene-specific primers (synthesized by IDT, Coralville, IA) and 12.5 l of Brilliant SYBR Green PCR master mix (2ϫ; Stratagene) containing green jump-start Taq ready mix. ROX (Stratagene) was used as a reference dye. The primers were selected using the Primer Express version 2.0 software (Applied Biosystems, Foster City, CA) as follows: ␤-actin: forward primer 5Ј-GGGAAATCGTGCGTGACATT-3Ј, reverse primer 5Ј-GCGGCAGTGGCCATCTC-3Ј; PEPCK: forward primer 5Ј-GCA-GAGCATAAGGGCAAGGT-3Ј, reverse primer 5Ј-TTGCCGAAGT-TGTAGCCAAA-3Ј. Fig. 2 . Dose-response studies to determine the effect of the active compounds on PEPCK gene expression in Dex-cAMP-activated rat hepatoma cells. The PEPCK mRNA was upregulated in all samples except for negative control by incubation H4IIE rat hepatoma cells with Dex-cAMP. PEPCK mRNA was normalized to ␤-actin mRNA. The effect of the active compounds applied in different doses or 10 nM insulin on PEPCK gene expression is represented as a ratio of PEPCK mRNA level relative to the response to Dex-cAMP activation alone (fold ratio is equal to 1.0). Lower fold ratio values represent greater inhibitory effect. The data represent the average of 4 experiments Ϯ SE. *P Ͻ 0.05 (ANOVA comparison with the samples treated only by Dex-cAMP). A: effect of 6-demethoxycapillarisin on PEPCK mRNA levels. B: effect of 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone on PEPCK mRNA levels. C: active compounds isolated from the Artemisia dracunculus extract. Fig. 3 . The additive effect of 10 nM insulin and various doses of 6-demethoxycapillarisin (A) and 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone (B) on the PEPCK gene expression. The PEPCK mRNA was upregulated in all treatments except for the negative control by incubation of the H4IIE rat hepatoma cells with Dex-cAMP. PEPCK mRNA was normalized to the ␤-actin mRNA. The effect of the treatments at each of the doses or 10 nM insulin on PEPCK gene expression is represented as a ratio of PEPCK mRNA level relative to the response to Dex-cAMP activation alone (fold ratio is equal to 1.0). Lower fold ratio values represent a greater inhibitory effect.
␤-Actin primers were selected from the RefSeq sequence with the accession no. NM_031144. Both primers reside on exon 4 of the rat ␤-actin gene (Rat Genomic Sequence Consortium, assembly version 3.4). These primers generated a 76-bp product from ␤-actin mRNA. PEPCK primers were selected from the RefSeq sequence with the accession no. NM_198780. The intron-spanning forward primer was selected to cover the exon 9 -10 boundary. The reverse primer was selected from exon 10. The oligos were synthesized by IDT. These primers generated a 74-bp product from PEPCK mRNA and a 207-bp product from genomic DNA.
Quantitative PCR (qPCR) amplifications were performed on an MX3000p system (Stratagene) using one cycle at 50°C for 2 min and one cycle of 95°C for 10 min, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. The dissociation curve was completed with one cycle of 1 min at 95°C, 30 s at 55°C, and 30 s at 95°C. Non-RT control and no-template control were included in each experiment as quality control steps.
PEPCK mRNA expressions were analyzed using the ⌬⌬C T method and normalized with respect to the expression of the ␤-actin housekeeping gene. The ⌬⌬C T values obtained from these analyses directly reflect the relative mRNA quantities for a specific gene in response to a treatment as relative to a calibrator. The Dex-cAMP treatment (positive control) served as the calibrator sample in this study. The PECPK gene expression of the calibrator sample was assigned to a value of 1.0. A value of Ͻ1.0 indicates transcriptional downregulation (inhibition of gene expression) relative to the calibrator. Amplification of specific transcripts was further confirmed by obtaining melting curve profiles. All samples were run in duplicate.
AMPK␣1 and -␣2 activity assay. AMP-activated protein kinase (AMPK) activity was assayed as previously described (6) . Briefly, AMPK was immunoprecipitated from 200 ug of H4IIE cell lysate using anti-AMPK␣1 (Upstate Biotechnology, Lake Placid, NY) or -␣2 (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies in 500 ul of buffer A (50 mM Tris ⅐ Hcl, pH 7.4, 150 mM NaCl, 50 mM NaF, 5 mM sodium pyrophosphate, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride, 5 ug/ml aproptin) at 4°C for 2 h. Immunocomplexes were washed with buffer A three times, buffer B containing 0.5 M NaCl and 62.5 mM NaF, and then reaction buffer (50 mM HEPES, pH 7.4, 1 mM dithiothreitol) three times. AMPK activity of immunocomplexes was determined by phosphorylation of SAMS peptide in reaction buffer containing 0.25 mM SAMS, 5 mM MgCl 2, and 10 uCi of [r-32 P]ATP for 10 min at 30°C with or without 200 M AMP stimulation. The reaction was terminated by spotting reaction mixtures onto P81 filter paper and rinsed in 1% (vol/vol) phosphoric acid with gentle stirring to remove free ATP. Phosphorylated substrate was measured by scintillation counting.
Western blot analysis. Cells were cultured as described above, and whole cell extracts were prepared in ice-cold lysis buffer [62.5 mM Tris ⅐ HCl (pH 6.8), 2% wt/vol SDS, 10% glycerol, 50 mM DTT, 0.01% wt/vol bromophenol blue] and centrifuged at 12 000 g for 20 min at 4°C. Equal amounts of protein (50 ug) from the supernatants were separated on SDS 10% polyacrylamide gels and blotted onto nitrocellulose membrane. Western blot analysis was performed with monoclonal phospho-Akt (Ser 473 ) antibodies according to the manufacturer's instructions (Cell Signaling Technology, Danvers, MA). After being washed, the blots were incubated with an anti-rabbit peroxidase-labeled secondary antibody and visualized using ECL Western Blotting Detection Reagent (GE Healthcare, Piscataway, NJ). After being stripped, the blots were probed with Akt2 (5B5) antibodies. Glucose production assay. H4IIE rat hepatoma cells were treated with Dex-cAMP in the presence or absence of 5 nM insulin (Sigma) or test compound (6-demethoxycapillarisin or 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone) for 5 h at 37°C. Cells were incubated for an additional 3 h in glucose production buffer (glucose-free Dulbecco's modified essential medium, pH 7.4, containing 20 mM sodium lactate and 2 mM sodium pyruvate without phenol red) with dexamethasone and 0.1 mM 8-CPT-cAMP in the presence or absence of 5 nM insulin or test compound. At the end of this incubation, 0.5 ml of medium was taken to measure the glucose concentration of the culture medium using the Amplex Red glucose assay kit (Invitrogen). Corrections for cell number were made on the basis of the protein concentration measured by the Bradford method.
Statistical analysis. Experimental observations are expressed as means Ϯ SE. One-way ANOVA was used to determine the significance of treatments. Tukey's multiple means comparison test was performed to determine the significance of the difference between the control and treatments. Treatments were considered significantly different if P Ͻ 0.05.
RESULTS
The ethylacetate extract of A. dracunculus and its fractions were tested for inhibitory activity of Dex-cAMP-induced PEPCK gene expression in an H4IIE rat hepatoma cell line (Fig. 1) . The membrane-permeable cAMP analog 8-CTPcAMP and the synthetic glucocorticoid dexamethasone were used to upregulate the PEPCK gene. A decrease in relative PEPCK mRNA level in cells treated with the test compounds or with insulin indicated an inhibitory effect and potential antidiabetic activity from the treatment. Untreated cells were used to measure the basal level of PEPCK expression. The ␤-actin gene expression was chosen as an internal standard since the level of ␤-actin mRNA remained unaffected by the treatments. The toxicity of the whole extract, subfractions of the extract, and purified compounds were determined by the standard MTT test (data not shown), and nontoxic doses were used for further experiments.
At 100 g/ml, the total extract repressed PEPCK expression by 60% (data not shown). Ten basic fractions, separated on the basis of time by HPLC fractionation of the total extract of A. dracunculus, were tested for PEPCK inhibitory activity. Fraction 7 (Fig. 1A) exhibited the highest inhibitory activity over PEPCK expression (PEPCK mRNA decreased Ͼ2-fold). Therefore, it was fractionated further into eight subfractions, and their effect on PEPCK transcription was evaluated (Fig.  1B) . Additional purification of active subfractions 7-1 and 7-8 yielded two bioactive compounds, identified by LC-MS and NMR as 6-demethoxycapillarisin and 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone, respectively (Fig. 2C) . The dose response of the two isolated bioactive compounds on the PEPCK mRNA expression from fraction 7 was then evaluated over nontoxic concentration ranges of 8.7-70 M for 6-demethoxycapillarisin and 36.8 -92 M for 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone (Fig. 2, A and B) . 6-Demethoxycapillarisin possessed stronger inhibitory activity on the PEPCK gene expression than 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone, with IC 50 equal to 43 and 61 M, respectively. In addition, 6-demethoxycapillarisin in combination with 10 nM insulin decreased the PEPCK gene expression twice as much as insulin alone (Fig. 3) , whereas the effects of 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone and insulin on the PEPCK gene expression were not additive.
The inhibitory effect of insulin over PEPCK transcription is mediated by the activation of PI3K and can be reversed by specific PI3K inhibitors such as LY-294002. The activity of this specific inhibitor can be used to determine whether the insulin-like effects of other bioactive compounds are also mediated through the PI3K pathway. Indeed, preincubation of Fig. 5 . The effects of the mitogen-activated protein kinase inhibitor PD-184352 (A) and p70 S6 kinase inhibitor rapamycin on the activity of the active compounds on the PEPCK gene expression. The PEPCK mRNA was upregulated in all treatments except for the negative control by incubation of the H4IIE rat hepatoma cells with Dex-cAMP. PEPCK mRNA was normalized to the ␤-actin mRNA. The effect of the treatments at each of the doses or 10 nM insulin on PEPCK gene expression is represented as a ratio of PEPCK mRNA level relative to the response to Dex-cAMP activation alone (fold ratio is equal to 1.0). Lower fold ratio values represent a greater inhibitory effect. In the experiments where the PD-184352 inhibitor was applied, the H4IIE cells were pretreated with 20 M for 30 min. In the experiments where the rapamycin was applied, the H4IIE cells were treated with 40 nM of rapamycin for 30 min. The data represent the average of 4 experiments Ϯ SE. A: effect of mitogenactivated protein kinase inhibitor PD-184352 on PEPCK mRNA downregulation by 50 M 6-demethoxycapillarisin or 80 M 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone. B: effect of the p70 S6 kinase inhibitor rapamycin on PEPCK mRNA downregulation caused by 50 M 6-demethoxycapillarisin or 80 M 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone.
the culture cells with 20 M LY-294002 also reversed the downregulation of PEPCK gene expression by 70 M 6-demethoxycapillarisin (Fig. 4A ), but only slightly by 75 M 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone (Fig. 4B) . Like insulin, 6-demethoxycapillarisin-induced Akt2 phosphorylation within the carboxy terminus at Ser 473 is significantly decreased by the PI3K inhibitor LY-294002 (Fig. 4C) . Other inhibitors were also incorporated into the assays to further characterize the mechanisms of action of the isolated compounds. Neither rapamycin, an inhibitor of p70 S6 kinase (p70 S6k ), or PD-184352, an inhibitor of mitogen-activated protein kinase (MAPK), exerted any significant effect on the PEPCK mRNA downregulation caused by the active compounds from A. dracunculus extract (Fig. 5) . On the other hand, compound C, an inhibitor of AMPK (21), completely reversed the effect of 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone on Dex-cAMPstimulated PEPCK gene expression in H4IIE cells (Fig. 6C) . This compound was able to increase the activity of the AMPstimulated AMPK␣2 catalytic subunit by 150%, whereas both compounds increased the basal activity of the AMPK␣1 subunuit within the same cells (Fig. 6, A and B) .
To assess the effect of the downregulation of PEPCK gene expression on glucose production in vitro, H4IIE rat hepatoma cells were incubated in medium containing pyruvate and lactate as substrates for gluconeogenesis. The H4IIE cell line is uniquely suited for these experiments because the physiological regulation of gluconeogenesis in response to hormones is maintained by the cultures (12) . Insulin (5 nM) and low concentrations of 6-demethoxycapillarisin (8.7 M) caused a significant decrease in glucose production, whereas higher concentrations of 6-demethoxycapillarisin (17.5 M) and 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone (36.8 M) were able to further repress glucose production to basal levels (Fig. 7) .
DISCUSSION
The pharmacological effectiveness of plant extracts is rarely substantiated with scientifically controlled clinical and animal studies. An ethanolic extract of A. dracunculus was recently shown (13) to reduce blood glucose concentrations in STZinduced diabetic mice as well as in genetically diabetic KK-A ␥ mice by 20 and 24%, respectively, after 7 days of treatment at 500 mg⅐kg Ϫ1 ⅐day Ϫ1 . The extract was also shown (13) to decrease liver PEPCK mRNA expression by 28% in rats made diabetic with the STZ treatment.
PEPCK is a key enzyme modulating hepatic gluconeogenesis, and its activity is closely correlated with hepatic glucose output (5) . PEPCK gene expression is upregulated by glucocorticoids and glucagon (through cAMP) during times of stress and fasting, when blood glucose concentrations need to be increased. Alternatively, PEPCK gene expression is downregulated by the increase in circulating blood insulin resulting from postprandial hyperglycemia. The impaired insulin response in the liver caused by insulin resistance secondary to type 2 diabetes, however, results in a continuous elevated expression of PEPCK due to the unopposed action of glucagon. This permits continuous hepatic glucose output, thereby contributing significantly to basal and fasting hyperglycemia and the complications associated with diabetes. A number of drugs currently in use, such as metformin and thiazolidinediones, are able to repress basal PEPCK expression but not hormoneinduced PEPCK expression, thus limiting their effectiveness for improving insulin sensitivity (2, 20) .
The activity-guided fractionation of the A. dracunculus extract led to the identification of its major components responsible for the inhibition of hormone-induced PEPCK mRNA transcription. Two polyphenolic substances, 6-demethoxycapillarisin and 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone, were isolated from active fraction 7 of the extract and shown to be the primary factors responsible for the downregulation of PEPCK gene expression. With the IC 50 values equal to 43 and 61 M, respectively, these compounds are more potent inhibitors of PEPCK mRNA transcription than metformin or thiazolidinediones, which have active doses ranging from 100 to 5,000 M in hepatoma cells (2, 20) . Although these identified compounds are primarily responsible for the PEPCK inhibitory activity of the total extract, partial inhibitory activity of other fractions and subfractions suggests that other inhibitors may also be present in the extract.
Polyphenols of plant origin, such as (Ϫ)-epigallocatechin gallate, were recently shown to mimic the effect of insulin on PEPCK gene expression by increasing PI3K, MAPK, and p70
S6k activities (17) . The PI3K pathway is a primary component of the insulin-signaling cascade in hepatocytes (1) . The effect of insulin or (Ϫ)-epigallocatechin gallate on the expression of its target genes, including PEPCK, can be reversed by the administration of specific inhibitors of PI3K, such as LY-294002. LY-294002 is a potent and selective cell-permeable inhibitor of PI3K (16) shown to abolish the insulin inhibition of Dex-cAMP-induced PEPCK gene transcription in hepatoma cells (1) . The inhibitory effect of 6-demethoxycapillarisin on PEPCK mRNA was significantly lower in the presence of this specific PI3K inhibitor, suggesting that it may suppress PEPCK gene expression by affecting the upstream components of the insulin-signaling pathway, such as PI3K. The effect of 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone, to the contrary, was not significantly influenced by the LY-294002 inhibitor and, therefore, is not likely to involve the PI3K insulin-like pathway. 6-Demethoxycapillarisin, like insulin, increases phosphorylation of Akt2 protein kinase at Ser 473 . LY-294002 significantly inhibits Akt2 phosphorylation induced by 6-demethoxycapillarisin or insulin (Fig. 4C) . The effect of Artemisia polyphenols on PEPCK gene expression was not affected by the inhibition of the the p70 S6k pathway with rapamycin (Fig. 5B) . Likewise, although activated Ras can downregulate cAMP-induced PEPCK gene expression in an insulin-independent manner through MAPK pathway (1), pretreatment with the MAPK inhibitor PD-184352 did not affect the PEPCK downregulation caused by Artemisia active compounds (Fig. 5A) .
The biguanidine drugs, such as metformin, and thiazolidinediones such as troglitazone were shown to exert a PI3K-independent downregulation of basal PEPCK gene expression in the liver of insulin-resistant patients (2, 20) through an AMPK-dependent mechanism. This pathway leads to the insulin-independent suppression of hepatic gluconeogenesis by phosphorylation and cytoplasmic sequestration of the mammalian target of rapamycin complex 2 transcriptional coactivator (8) . Both active compounds from the A. dracunculus extract are capable of increasing basal activity of ubiquitously expressed AMPK␣1 catalytic subunit, but only dihydroxy-4-methoxydihydrochalcone significantly increases AMP-stimulated activity of the liver-specific AMPK␣2 catalytic subunit. Moreover, downregulation of PEPCK mRNA expression by the dihydrochalcone is completely reversed by AMPK inhibitor compound C (Fig. 6) .
In conclusion, 6-demethoxycapillarisin and 2Ј,4Ј-dihydroxy-4-methoxydihydrochalcone from an A. dracunculus extract were identified as active compounds responsible for decreasing PEPCK overexpression in the liver cells of diabetic rodents. These compounds may act through insulin-like and insulinindependent pathways to achieve the suppression of both PEPCK gene expression and gluconeogenesis in the hepatocytes. Preliminary clinical (14) testing also suggested that the extract attenuated hyperinsulinemia in mildly diabetic patients. Thus, the A. dracunculus extract, or the compounds contained therein, may be useful for the prevention and treatment of diabetes and related disorders.
